The USPSTF found inadequate Prediabetes prevention evidence that screening Immunity enhancing supplements type 2 Beetroot juice for weight loss or Prediabetea Prediabetes prevention to improvements in mortality Prediabetes prevention Preidabetes morbidity. Prediabehes is further increased with a family history of Prediabetes prevention two diabetes, age over 45, African, Latino or Native American ancestry, smoking, and certain medications, including steroids, anti-psychotics, and HIV medication. Journal of Pediatrics. Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry. Then move on to the next change you need to make. twelve year follow-up of the Ely cohort. Davis, MD, MPH University of Pittsburgh, Pittsburgh ; Katrina E.

Video

You’ve Got Prediabetes. What now?

Prediabetes prevention -

With prediabetes, there are simple steps you can take to change things, such as adapting your food choices and increasing your daily physical activity to lose weight, if needed. Breadcrumb Home About Diabetes With prediabetes, action is the best medicine. You have the power to change things.

What it Means and What You Can Do There are no clear symptoms of prediabetes so you may have it and not know it. Lifestyle Change Programs A CDC-recognized lifestyle change program could cut your risk of developing type 2 diabetes in half. Learn More. Build a Healthier Future With prediabetes, there are simple steps you can take to change things, such as adapting your food choices and increasing your daily physical activity to lose weight, if needed.

Eat To Win, Every Day Move To Feel Better. Read More. B recommendation. Of persons with diabetes, Quiz Ref ID Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US.

It is also associated with increased risks of cardiovascular disease CVD , nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis 4 - 6 and was estimated to be the seventh leading cause of death in the US in The US Preventive Services Task Force USPSTF concludes with moderate certainty that screening for prediabetes and type 2 diabetes and offering or referring patients with prediabetes to effective preventive interventions has a moderate net benefit Table.

See the Table for more information on the USPSTF recommendation rationale and assessment and the eFigure in the Supplement for information on the recommendation grade.

See the Figure for a summary of the recommendation for clinicians. For more details on the methods the USPSTF uses to determine the net benefit, see the USPSTF Procedure Manual. Overweight and obesity are the strongest risk factors for developing prediabetes and type 2 diabetes in adults.

A large body of evidence demonstrates strong associations between prevalence of diabetes and social factors such as socioeconomic status, food environment, and physical environment. A difference in body fat composition in Asian persons results in underestimation of risk based on BMI thresholds used to define overweight in the US.

Prediabetes and type 2 diabetes can be detected by measuring fasting plasma glucose or HbA 1c level, or with an oral glucose tolerance test.

HbA 1c is a measure of long-term blood glucose concentration and is not affected by acute changes in glucose levels caused by stress or illness.

Because HbA 1c measurements do not require fasting, they are more convenient than using a fasting plasma glucose level or an oral glucose tolerance test. Both fasting plasma glucose and HbA 1c levels are simpler to measure than performing an oral glucose tolerance test.

The oral glucose tolerance test is done in the morning in a fasting state; blood glucose concentration is measured 2 hours after ingestion of a g oral glucose load.

The diagnosis of type 2 diabetes should be confirmed with repeat testing. Evidence on the optimal screening interval for adults with an initial normal glucose test result is limited.

Cohort and modeling studies suggest that screening every 3 years may be a reasonable approach for adults with normal blood glucose levels. Both lifestyle interventions that focus on diet, physical activity, or both and metformin have demonstrated efficacy in preventing or delaying progression to diabetes in persons with prediabetes.

Clinicians and patients may want to consider several other factors as they discuss preventive interventions for prediabetes.

In the Diabetes Prevention Program DPP study which serves as a model for many lifestyle intervention programs in the US , lifestyle intervention was more effective than metformin in preventing or delaying diabetes. In addition to preventing progression to diabetes, lifestyle interventions have a beneficial effect on weight, blood pressure, and lipid levels increasing high-density lipoprotein cholesterol levels and lowering triglyceride levels.

Metformin has a beneficial effect on weight, but it does not appear to affect blood pressure, or to consistently improve lipid levels. The USPSTF recommends offering or referring adults with a BMI of 30 or greater to intensive, multicomponent behavioral interventions.

This recommendation replaces the USPSTF recommendation statement on screening for abnormal blood glucose levels and type 2 diabetes in asymptomatic adults. In , the USPSTF recommended screening for abnormal blood glucose levels as part of cardiovascular risk assessment in adults aged 40 to 70 years who have overweight or obesity.

The USPSTF also recommended that clinicians should offer or refer patients with abnormal blood glucose levels to intensive behavioral counseling interventions to promote a healthful diet and physical activity.

Based on data suggesting that the incidence of diabetes increases at age 35 years compared with younger ages 22 and on the evidence for the benefits of interventions for newly diagnosed diabetes discussed below , the USPSTF has decreased the age at which to begin screening to 35 years.

To update its recommendation statement, the USPSTF commissioned a systematic review 2 , 23 of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant adults and preventive interventions for those with prediabetes.

This review focused on direct evidence on the benefits and harms of screening for prediabetes and type 2 diabetes and the benefits and harms of interventions such as behavioral counseling focused on diet, physical activity, or both, or pharmacotherapy for glycemic, blood pressure, or lipid control, compared with no treatment or usual care for screen-detected prediabetes and type 2 diabetes or recently diagnosed type 2 diabetes.

The review also looked at the evidence on the effectiveness of interventions for prediabetes to delay or prevent progression to type 2 diabetes. In the Ely study, the treatment of persons with screen-detected diabetes was managed by primary care clinicians as they deemed appropriate.

Neither trial found a reduction in all-cause or type-specific mortality with screening compared with no screening over approximately 10 years of follow-up, which notably may have been too short to detect an effect on health outcomes.

Neither trial found statistically significant differences in cardiovascular events, quality of life, nephropathy, or neuropathy between screening and control groups, but data collection for these outcomes was limited to a minority of trial participants. One randomized clinical trial ADDITION-Europe 30 - 33 evaluated interventions for persons with screen-detected type 2 diabetes.

It found no difference over 5 to 10 years of follow-up between an intensive multifactorial intervention aimed at controlling glucose, blood pressure, and cholesterol levels and routine care in the risk of all-cause mortality, cardiovascular-related mortality, occurrence of a first cardiovascular event, chronic kidney disease, visual impairment, or neuropathy.

Follow-up may have been too short in this trial to detect an effect on the health outcomes of interest. Thirty-eight trials that assessed behavioral or pharmacologic interventions for prediabetes reported on health outcomes.

Follow-up duration in most of these trials may have been too short to detect an effect on health outcomes. One trial, the Da Qing Diabetes Prevention Study comparing a 6-year lifestyle intervention diet, exercise, or both with control, found lower all-cause mortality and CVD-related mortality in the combined intervention groups vs control group at 23 and 30 years of follow-up, though not at 20 years of follow-up all-cause mortality: The UK Prospective Diabetes Study UKPDS and 2 other studies reported the effect of interventions for newly diagnosed diabetes on health outcomes.

The UKPDS found that all-cause mortality, diabetes-related mortality, and myocardial infarction were improved with intensive glucose control with sulfonylureas or insulin over 20 years year posttrial assessment but not at shorter follow-up.

Intensive glucose control was associated with a decreased risk for all-cause mortality relative risk [RR], 0. The other 2 studies found no statistically significant difference between intervention and control groups in all-cause mortality and risk of myocardial infarction; however, these studies were limited by short duration of follow-up, small study size, or both.

The Diabetes Education and Self Management for Ongoing and Newly Diagnosed DESMOND trial 39 , 40 found no statistically significant difference in all-cause mortality between persons randomly assigned to group education and those randomly assigned to the control group over 1 and 3 years of follow-up.

Quiz Ref ID Twenty-three trials compared lifestyle interventions with a control group for delaying or preventing the onset of type 2 diabetes. Most of the trials focused on persons with impaired glucose tolerance.

Meta-analysis of the 23 trials found that lifestyle interventions were associated with a reduction in progression to diabetes pooled RR, 0. In post hoc analyses, the DPP reported that lifestyle intervention was effective in all subgroups and treatment effects did not differ by age, sex, race and ethnicity, or BMI after 3 years of follow-up.

Several trials also reported the effects of lifestyle interventions on intermediate outcomes. Quiz Ref ID Fifteen trials evaluated pharmacologic interventions to delay or prevent diabetes. Two trials reported the effects of metformin on intermediate outcomes. Some of the trials reporting on the benefits of screening and interventions for prediabetes and type 2 diabetes also reported harms.

Overall, the ADDITION-Cambridge and Ely trials, and a pilot study of ADDITION-Cambridge, 28 , 29 , 44 - 46 did not find clinically significant differences between screening and control groups in measures of anxiety, depression, worry, or self-reported health.

However, the results suggest possible short-term increases in anxiety at 6 weeks among persons screened and diagnosed with diabetes compared with those screened and not diagnosed with diabetes. Harms of interventions for screen-detected or recently diagnosed type 2 diabetes were sparsely reported and, when reported, were rare and not significantly different between intervention and control groups across trials.

Several trials reported on harms associated with interventions for prediabetes. Four studies of pharmacotherapy interventions reported on any hypoglycemia and found no difference between interventions and placebo over 8 weeks to 5 years. Three trials found higher rates of gastrointestinal adverse events associated with metformin.

Although not reported in studies, lactic acidosis is a rare but potentially serious adverse effect of metformin, primarily in persons with significant renal impairment.

A draft version of this recommendation statement was posted for public comment on the USPSTF website from March 16 to April 12, Many comments agreed with the USPSTF recommendation.

In response to public comment, the USPSTF clarified that disparities in the prevalence of prediabetes and type 2 diabetes are due to social factors and not biological ones, and incorporated person-first language when referring to persons who have overweight or obesity.

Some comments requested broadening the eligibility criteria for screening to all adults, or to persons with any risk factor for diabetes, and not confined to persons who have overweight or obesity.

The USPSTF appreciates these perspectives; however, the available evidence best supports screening starting at age 35 years. The USPSTF also added language clarifying that overweight and obesity are the strongest risk factors for developing prediabetes and type 2 diabetes.

In response to comments, the USPSTF also noted that metformin appears to be effective in reducing the risk of progression from prediabetes to diabetes in persons with a history of gestational diabetes, based on post hoc analyses of the DPP and DPPOS.

More studies are needed on the effects of screening on health outcomes that enroll populations reflective of the prevalence of diabetes in the US, particularly racial and ethnic groups that have a higher prevalence of diabetes than White persons.

More US data are needed on the effects of lifestyle interventions and medical treatments for screen-detected prediabetes and diabetes on health outcomes over a longer follow-up period, particularly in populations reflective of the prevalence of diabetes.

More research is needed on how best to increase uptake of lifestyle interventions, especially among populations at highest risk for progression to diabetes and adverse health outcomes. Clinical trials and additional modeling studies are needed to better elucidate the optimal frequency of screening and the age at which to start and stop screening.

More research is needed on the natural history of prediabetes, including the identification of factors associated with risk of progression to diabetes or reversion to normoglycemia. If the results are normal, it recommends repeat screening at a minimum of 3-year intervals.

The American Association of Clinical Endocrinology 49 recommends universal screening for prediabetes and diabetes for all adults 45 years or older, regardless of risk factors, and screening persons with risk factors for diabetes regardless of age. Testing for prediabetes and diabetes can be done using a fasting plasma glucose level, 2-hour plasma glucose level during a g oral glucose tolerance test, or HbA 1c level.

It recommends repeat screening every 3 years. Corresponding Author: Karina W. Davidson, PhD, MASc, Feinstein Institutes for Medical Research, E 59th St, Ste 14C, New York, NY chair uspstf. Correction: This article was corrected on October 26, , to fix an unclear diagnostic testing standard in the Practice Considerations section.

The US Preventive Services Task Force USPSTF members: Karina W. Davidson, PhD, MASc; Michael J. Barry, MD; Carol M.

Mangione, MD, MSPH; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Chyke A. Doubeni, MD, MPH; Alex H. Krist, MD, MPH; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Douglas K. Owens, MD, MS; Lori Pbert, PhD; Michael Silverstein, MD, MPH; James Stevermer, MD, MSPH; Chien-Wen Tseng, MD, MPH, MSEE; John B.

Wong, MD. Author Contributions: Dr Davidson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.

All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings. The US Congress mandates that the Agency for Healthcare Research and Quality AHRQ support the operations of the USPSTF.

AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication. Disclaimer: Recommendations made by the USPSTF are independent of the US government.

They should not be construed as an official position of AHRQ or the US Department of Health and Human Services. Through the program, participants:.

If you have prediabetes, ask your health care provider about the National DPP lifestyle change program. The best time to prevent type 2 diabetes is now.

Skip directly to site content Skip directly to search. Español Other Languages. The Surprising Truth About Prediabetes. Español Spanish.

Minus Related Pages. Prediabetes Flies Under the Radar You can have prediabetes for years without symptoms. Talk to your doctor about getting your blood sugar tested if you have any of the risk factors for prediabetes, including: Being overweight Being 45 years or older Having a parent, brother, or sister with type 2 diabetes Being physically active less than 3 times a week Ever having gestational diabetes diabetes during pregnancy or giving birth to a baby who weighed more than 9 pounds Race and ethnicity are also a factor.

Diabetes Is Harder to Live With Than Prediabetes People with prediabetes have a higher risk of heart disease and stroke. Through the program, participants: Work with a trained coach to make lasting lifestyle changes.

Discover how to eat healthy and add more physical activity into their day. Find out how to manage stress, stay motivated, and solve problems that can slow progress. Type 1 and Type 2: Not the Same.

Type 2 can be prevented or delayed through lifestyle changes. Type 1 often starts quickly and has severe symptoms; type 2 is gradual and develops over many years. Type 1 usually occurs in children, teens, and young adults.

Type 2 occurs most often in older people, but is becoming more common in children, teens, and young adults. People with type 1 must use insulin every day to survive. Prediabetes can develop into type 2 diabetes, but not type 1.

Updated: Prediabetes prevention. There are more Herbal cancer prevention Prediabetes prevention million people with the condition, and lrevention are Prediabetss when they prevebtion young, even in adolescence. Perhaps more astonishing—and worrying—is that prediabetes, the condition that leads to type 2 diabetesnow affects 98 million people. You can still prevent or delay type 2 diabetes by losing weight—even a modest amount—with the help of dietary changes, stress reduction, and physical activity. Taking medication can also help. Prediabetes is when Prediabeetes glucose sugar levels in your blood are higher than normal, Prediabetes prevention not high enough to Prediabetes prevention Prrediabetes Prediabetes prevention diabetes. Insulin helps your body to change sugars and starches into energy. Your blood glucose levels increase when your body isn't making enough insulin or insulin isn't working as effectively as it has in the past. Approximately 1 in 3 adults in North Carolina has prediabetes. There are no symptoms of prediabetes.